Company: JUNS
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001641172-25-001261
Chunk: 341

Company: JUPITER NEUROSCIENCES, INC.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 10
Chunk 341
---
2025 upon exercise of vested options.

    (5)
    Includes
    870,871 shares of common stock that may be acquired within 60 days of March 28, 2025 upon exercise of vested options.

    (6)
    Includes 1,171,688 shares of common stock that may be acquired within 60
days of March 28, 2025 upon exercise of vested options.

    (7)
    Includes
    193,737 shares of common stock that may be acquired within 60 days of March 28, 2025 upon exercise of vested options.

    (8)
    Includes
    176,993 shares of common stock that may be acquired within 60 days of March 28, 2025 upon exercise of vested options.

    (9)
    Includes
    170,659 shares of common stock that may be acquired within 60 days of March 28, 2025 upon exercise of vested options.

    (10)
    Includes
    180,855 shares of common stock that may be acquired within 60 days of March 28, 2025 upon exercise of vested options.

    (11)
    Represents shares of common stock beneficially owned by Christer Rosén,
Marshall Hayward, Ph.D., Saleem Elmasri, Alison D. Silva, Alexander Rosén, Nicholas H. Hemmerly, Julie Kampf, Allison W. Brady,
and Holger Weis, as shown in the table above and in the footnotes to such table.

    (12)
    Includes
    514,609 shares of common stock that may be acquired within 60 days of March 12, 2025 upon exercise of vested options.

    (13)
    Includes
    326,319 shares of common stock that may be acquired within 60 days of March 12, 2025 upon exercise of vested options.

117

Securities
Authorized for Issuance under Equity Compensation Plans

The
following table provides information as of December 31, 2024, regarding our compensation plans under which equity securities are authorized
for issuance:

    Plan category 
    Number of securities to be issued upon exercise of outstanding options,  warrants and rights  
    Weighted-average exercise price of outstanding options, warrants and rights  
    Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) 

    (a)  
    (b)  
    (